Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation

PartnershipPositive

AI Analysis

Summary

Ultima Genomics was selected for a large-scale study in which IMU Biosciences and UK Biobank will generate a single-cell immune profiling AI foundational dataset from 80,000 UK Biobank blood samples. The study uses Ultima's UG200 Sequencing Platform and Waters Corporation's BD Rhapsody Single-Cell Platform.

Outcome Details

Ultima Genomics selected for large-scale immune profiling study with IMU Biosciences, UK Biobank and Waters Corporation to generate a single-cell immune profiling AI foundational dataset from 80,000 blood samples.

Importance:5/10

Sentiment:

0.60

partnershipgenomicssingle-cellimmune profilingAIUK Biobanksequencing

Related Companies

$WAT

Read the original article

Published by PR Newswire Biotech on October 19, 2026 7:05 AM

Read Original